Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

<div>Rate of patients with neovascular age-related macular degeneration aged ≥90 years that experience a loss of ≥15 ETDRS letters in best-corrected visual acuity during treatment with either Aflibercept (red) or Ranibizumab (blue).</div>

Journal of Ophthalmology

fig3

Figure 3

Figure 3: Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy 